Phlebaven, 500 mg 32 pcs

The drug Phlebaven^® is indicated for the therapy of symptoms of chronic vein diseases (elimination and relief of symptoms).

Therapy of symptoms of venous and lymphatic insufficiency:

• pain;
• lower limb cramps;
• sensation of heaviness and expansion in legs;
• “tired legs”

therapy of manifestations of venous-lymphatic insufficiency:

• lower extremity edema;
• trophic changes of the skin and subcutaneous tissue;
• venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Indications

The drug Flebaven® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:

pain;
spasms of the lower extremities;
feeling of heaviness and fullness in the legs;
“tired” legs.

Treatment of manifestations of venous-lymphatic insufficiency:

swelling of the lower extremities;
trophic changes in the skin and subcutaneous tissue;
venous trophic ulcers.

Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

venotonic and venoprotective agent

Special instructions

Before you start taking Flebaven®, it is recommended to consult your doctor.
In case of exacerbation of hemorrhoids, the use of Flebaven® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.
In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings helps improve blood circulation.

Contact your doctor immediately if your condition worsens or does not improve during treatment.

No effect.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

for 1 tablet

Core:

Purified micronized flavonoid fraction, substance – granules 613.00 mg

[Active substance of the substance – granules:

Purified micronized flavonoid fraction [diosmin (90%) 450 mg, flavonoids in terms of hesperidin (10%) 50 mg] 500.00 mg

Excipients of the substance – granules:

Microcrystalline cellulose, povidone K-30]

Excipients:

Sodium carboxymethyl starch, talc, magnesium stearate

Film shell:

Opadry orange 03Н325991

1 Opadry orange 03Н32599 contains:

– hypromellose

– titanium dioxide (E171)

– talc

– propylene glycol

– iron oxide yellow dye (E172)

– red iron oxide dye (E172)

Pregnancy

Pregnancy

Experiments on animals did not reveal teratogenic effects.

To date, there have been no reports of adverse effects when using the drug by pregnant women.

Breastfeeding period

Due to the lack of data regarding the excretion of the drug in breast milk, taking the drug is not recommended for women during breastfeeding.

Effect on reproductive function

Reproductive toxicity studies showed no effect on reproductive function in rats of either sex.

Contraindications

Hypersensitivity to the active or excipients included in the drug.
It is not recommended to take the drug during breastfeeding.

Side Effects

Side effects of the hesperidin + diosmin combination observed in clinical studies were mild. Disorders from the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed.

Classification of the frequency of side effects recommended by the World Health Organization (WHO):

very common ≥ 1/10

often ≥ 1/100 to < 1/10

uncommon ≥ 1/1000 to < 1/100

rarely from ≥ 1/10000 to < 1/1000

very rare <1/10000

frequency unknown cannot be estimated from available data.

From the central nervous system:

rarely: dizziness, headache, general malaise.

From the digestive system:

often: diarrhea, dyspepsia, nausea, vomiting;

uncommon: colitis;

frequency unknown: abdominal pain.

From the skin:

rarely: skin rash, itching, urticaria;

frequency unknown: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema.

INFORM YOUR DOCTOR ABOUT ANY ADVERSE REACTIONS AND SENSATIONS YOU HAVE, INCLUDING THOSE NOT MENTIONED IN THIS INSTRUCTION, AS WELL AS CHANGES IN LABORATORY VALUES DURING THE THERAPY.

Interaction

Not noted.

YOU SHOULD INFORM YOUR DOCTOR ABOUT ALL MEDICINES YOU ARE TAKEN.

Overdose

No cases of overdose have been described.

In case of overdose of Phlebaven®, seek medical help immediately.

Clinical pharmacology

Pharmacodynamics

The combination of hesperidin + diosmin has venotonic and angioprotective properties. Reduces the distensibility of veins and venous stagnation, in microcirculation – reduces capillary permeability and increases their resistance, improves venous hemodynamics. It affects the following venous plethysmographic parameters: venous capacity, venous distensibility, time of venous emptying. The optimal effect is achieved by taking 2 tablets per day.

The combination of hesperidin + diosmin increases venous tone by reducing the time of venous emptying. In patients with signs of severe microcirculation disorders, an increase in capillary resistance is observed after using the combination of hesperidin + diosmin.

The combination of hesperidin + diosmin is effective in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Pharmacokinetics

Flebaven® is primarily excreted through the intestines. On average, about 14% of the dose taken is excreted by the kidneys.

The half-life is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Storage conditions

At a temperature not exceeding 25 °C, in the original packaging.

Keep out of the reach of children.

Shelf life

2 years.

Do not use the drug after the expiration date.

Manufacturer

KRKA-RUS, Russia